Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Key facts
- Who runs it
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Where
- Bethesda, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 54 people, planned
- Started
- 12 Nov 2025
- Expected to end
- Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pfizer-BioNTech mRNA COVID-19 vaccine
- Novavax recombinant protein vaccine
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- 18-79 years old
- Have a history of any of the following risk factors for severe COVID:; Current:; Age > 65 years old; Physical inactivity (defined as <150 mins of moderate activity per week or <75 mins of vigorous activity per week); HIV with CD4 count ≥ 500 cells/ul; Smoker; Obesity with BMI ≥ 30 and < 40; History of:; Asthma; Depression or other mood disorder; Schizophrenia spectrum disorder; Cerebrovascular disease; Heart failure; Coronary artery disease; Cardiomyopathy; Pulmonary embolism; Pulmonary hypertension; Cystic fibrosis; Bronchiectasis; Chronic obstructive pulmonary disease; Interstitial Lung Disease; Stage I or II chronic kidney disease (Stage 1 defined as normal GFR (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2); Gestational diabetes; Type 1 diabetes with most recent HgbA1C < 7.5%; Type 2 diabetes with most recent HgbA1C < 7.5%; Liver disease without cirrhosis and with liver enzyme levels (AST and ALT) no greater than three times the upper limit of normal; Smoking
- Military Health System beneficiary and DEERS eligible
- Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
- Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months
Who cannot take part
- Received a COVID-19 vaccine in the last 3 months
- Active use of immune modulating medications; Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function
- Diagnosed with immunocompromised stated; Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen)
- History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
- Tested positive for COVID-19 in the past 3 months; Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit
- Diabetes with the most recent HgbA1C ≥ 7.5
- Stage III or greater chronic kidney disease; Defined as estimated glomerular filtration rate < 60 ml/min/1.73m2)
- History of solid organ or bone marrow transplant
- Active malignancy; Defined as any cancer that is currently being treated or has shown evidence of progression within the past year
- HIV with a CD4 cell count < 500 cells/ul
- Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels (AST or ALT) greater than three times the upper limit of normal
- Obesity with a BMI ≥ 40
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in United States.
- Walter Reed National Military Medical CenterBethesda, United StatesContact: Irma BarahonaTaking people
About the trial
What the trial wants to find out
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
The 2 groups in the trial
- For fall of 2026, Arm 1 of the study will be the Pfizer-BioNTech mRNA COVID-19 vacExisting treatment, for comparison
Arm 1 of the study will be Pfizer-BioNTech mRNA COVID-19 vaccine
Treatment: Pfizer-BioNTech mRNA COVID-19 vaccine
- For fall of 2026, Arm 2 of the study will be the Novavax recombinant protein vaccineExisting treatment, for comparison
Arm 2 of the study will be the Novavax recombinant protein vaccine
Treatment: Novavax recombinant protein vaccine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
- Criteria questions
- Built from NCT07287137, who can take part
- Record updated
- 2 November 2026